Several other analysts also recently issued reports on the stock. ValuEngine raised shares of Soleno Therapeutics from a hold rating to a buy rating in a research note on Tuesday, July 10th. Roth Capital began coverage on shares of Soleno Therapeutics in a research note on Friday, June 22nd. They issued a buy rating and a $14.00 price objective for the company. Finally, Noble Financial set a $4.00 price objective on shares of Soleno Therapeutics and gave the stock a buy rating in a research note on Wednesday, May 16th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average target price of $7.50.
Shares of NASDAQ SLNO opened at $2.42 on Wednesday. The stock has a market capitalization of $53.38 million, a price-to-earnings ratio of -1.79 and a beta of 5.10. Soleno Therapeutics has a 1 year low of $1.32 and a 1 year high of $3.70.
Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.12). equities analysts forecast that Soleno Therapeutics will post -1.37 EPS for the current year.
Several large investors have recently modified their holdings of the company. Vivo Capital LLC increased its position in shares of Soleno Therapeutics by 8.1% during the second quarter. Vivo Capital LLC now owns 4,359,683 shares of the company’s stock worth $10,202,000 after acquiring an additional 326,149 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Soleno Therapeutics during the second quarter worth approximately $104,000. Finally, Trellus Management Company LLC purchased a new position in shares of Soleno Therapeutics during the second quarter worth approximately $302,000. 46.59% of the stock is currently owned by institutional investors and hedge funds.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development.
Featured Article: Trading Strategy
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.